1. An electronic equipment comprising:
a housing;
a connection-use circuit board provided to define in said housing a one side space and a remaining side space, with a plurality of cooling air-use openings and a plurality of electrical connectors being provided on said connection-use circuit board;
a plurality of control modules provided to reside in said one side space while corresponding to said cooling air-use openings respectively and being electrically connected to said connection-use circuit board through said electrical connectors respectively;
a plurality of fan modules provided in said remaining side space and arranged to include fans corresponding to said cooling air-use openings respectively; and
a duct member placed in said remaining side space and provided between said connection-use circuit board and each of said fan modules for connecting an exhaust port of each said fan to a corresponding one of said cooling air-use openings.
2. The equipment according to claim 1, wherein said duct member has:
a plurality of inflow ports connected to exhaust ports of said fans respectively;
a plurality of outflow ports connected to said cooling air-use openings respectively; and
a plurality of flow paths for causing each said inflow port and its associated one of said outflow ports to be coupled together while letting them be grouped per each said cooling air-use opening, and wherein
said duct member is comprised of a plurality of divided bodies in such a way as to enable formation by division of at least one of said flow paths.
3. The equipment according to claim 2, wherein respective ones of said flow paths are coupled together for communication therebetween.
4. The equipment according to claim 2, wherein a flow path system made up of each said inflow port and each said flow path plus each said outflow port of said duct member is formed to have a shape which causes a cooling air to hardly flow back from each said exhaust port toward each said inflow port.
5. The equipment according to claim 2, wherein an openclose valve is provided at each said inflow port for allowing a cooling air from each said fan to flow into inside of each said flow path and for avoiding reverse flow thereof.
6. The equipment according to claim 5, wherein said openclose valve is made of a material having flexibility.
7. The equipment according to claim 1, wherein each fan of each said fan module is arranged as a sirocco fan for performing air intake from an axial direction and air exhaust in a radial direction, and wherein an exhaust port of each said fan is disposed to face inward.
8. The equipment according to claim 1, wherein when any one fan module of said fan modules stops its operation, control is made to cause a remaining fan module to increase in air blow power.
9. The equipment according to claim 1, wherein each said control module is such that electronic components acting as a heating body is disposed in close proximity to said cooling air-use openings.
10. The equipment according to claim 1, further comprising:
a power supply module disposed adjacent to each said control module in the one side space of said housing; and
a thermal insulating ventilation path formed between said power supply module and each said control module.
11. The equipment according to claim 10, wherein said power supply module includes an air inlet fan, and wherein
a communicating hole is formed on a downstream side of said thermal insulating ventilation path, for causing a cooling air which cools down each said control module to escape toward an outside through the air inlet fan of said power supply module.
12. The equipment according to claim 10, wherein said control module comprises a converter circuit for converting a high voltage input being supplied from said power supply module into a low voltage output, and wherein said converter circuit is disposed near said cooling air-use openings.
13. The equipment according to claim 1, wherein at least either one of said cooling air-use openings of said connection-use circuit board is formed of a plurality of openings.
14. The equipment according to claim 13, wherein said plurality of openings are provided to reduce a length of a wiring pattern of said connection-use circuit board.
15. The equipment according to claim 1, further comprising:
a battery module disposed adjacent to each said fan module in the remaining side space of said housing, wherein said battery module has a plurality of communicating holes formed in each of a first side face neighboring upon each said fan module and in a second side face facing an outside, for supplying an outside air from each communication hole of the second side face to said fan module through each communicating hole of said first side face.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-204. (canceled)
205. A method of promoting the development of an immune response against a target cell in a subject, comprising administering to said subject a Spi2A polypeptide or an Spi2A polypeptide equivalent.
206. The method of claim 205, wherein the target cell is a tumor cell or a cell that is infected by a pathogen.
207. The method of claim 206, wherein the target cell is a tumor cell.
208. The method of claim 207, wherein the tumor cell is a cell from a breast cancer, lung cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, lymphoma, or leukemia.
209. The method of claim 206, wherein the target cell is a cell that is infected by a pathogen.
210. The method of claim 209, wherein the pathogen is a virus.
211. The method of claim 210, wherein the virus is HIV, HSV, or ADV.
212. The method of claim 205, further defined as a method of inhibiting a cathepsin in a subject.
213. The method of claim 212, wherein the cathepsin is cathepsin B, cathepsin H, cathepsin L, cathepsin S, cathepsin C, cathepsin K, cathepsin O, cathepsin F, cathepsin V, cathepsin X, or cathepsin W.
214. The method of claim 205, wherein the subject has an immune disorder.
215. The method of claim 214, wherein the immune disorder is an autoimmune disorder or a disorder associated with abnormal antigen presentation.
216. The method of claim 205, wherein the cell is contacted with an Spi2A polypeptide.
217. The method of claim 205, wherein the cell is contacted with an Spi2A polypeptide equivalent.
218. The method of claim 217, wherein the Spi2A polypeptide equivalent is a polypeptide from Serpin B1, Serpin B2, Serpin B3, Serpin B4, Serpin B6, Serpin B8, or Serpin B9.
219. The method of claim 205, wherein the Spi2A polypeptide or Spi2A polypeptide equivalent is a polypeptide comprising 4 to 8 consecutive amino acid residues of the amino acid sequences MAGVGCCA or FVVAECCM.
220. The method of claim 205, wherein said Spi2A polypeptide or said Spi2A polypeptide equivalent further comprises an expression cassette comprising a promoter active in said cell, operably linked to a polynucleotide encoding an Spi2A polypeptide or an Spi2A polypeptide equivalent.
221. The method of claim 220, wherein said expression cassette is carried in a viral vector.
222. The method of claim 221, wherein said viral vector is an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a vaccinia viral vector, or a pox viral vector.
223. The method of claim 220, wherein said expression cassette is carried in a nonviral vector.
224. The method of claim 223, wherein said nonviral vector is a liposome.
225. The method of claim 220, wherein the promoter is a constitutive promoter, an inducible promoter or a tissue-specific promoter.
226. The method of claim 205, wherein said Spi2A polypeptide or said Spi2A polypeptide equivalent is obtained from media of cultured cells and applied to the surface of said cell.
227. The method of claim 205, wherein said Spi2A polypeptide or said Spi2A polypeptide equivalent induces a humoral or cell-mediated immune response in the subject.
228. The method of claim 227, wherein the humoral or cell-mediated immune response is to a tumor in the subject.
229. The method of claim 227, wherein the humoral or cell-mediated immune response is to a virus.
230. The method of claim 205, further comprising administering an antigen to the subject.
231. A method for facilitating the differentiation of a T lymphocyte into a memory T lymphocyte, comprising contacting said T lymphocyte with a Spi2A polypeptide or a Spi2A polypeptide equivalent.
232. The method of claim 231, wherein the cell is contacted with an Spi2A polypeptide.
233. The method of claim 231, wherein the cell is contacted with an Spi2A polypeptide equivalent.
234. The method of claim 233, wherein the Spi2A polypeptide equivalent is a polypeptide from Serpin B1, Serpin B2, Serpin B3, Serpin B4, Serpin B6, Serpin B8, or Serpin B9.
235. The method of claim 231, wherein the Spi2A polypeptide or Spi2A polypeptide equivalent is a polypeptide comprising 4 to 8 consecutive amino acid residues of the amino acid sequences MAGVGCCA or FVVAECCM.
236. A method of inhibiting a cysteine cathepsin in a subject, comprising administering to said subject a Spi2A polypeptide or an Spi2A polypeptide equivalent.
237. The method of claim 236, wherein the cell is contacted with an Spi2A polypeptide.
238. The method of claim 236, wherein the cell is contacted with an Spi2A polypeptide equivalent.
239. The method of claim 238, wherein the Spi2A polypeptide equivalent is a polypeptide from Serpin B1, Serpin B2, Serpin B3, Serpin B4, Serpin B6, Serpin B8, or Serpin B9.
240. The method of claim 236, wherein the Spi2A polypeptide or Spi2A polypeptide equivalent is a polypeptide comprising 4 to 8 consecutive amino acid residues of the amino acid sequences MAGVGCCA or FVVAECCM.
241. A pharmaceutical composition, comprising:
(a) a Spi2A polypeptide or an Spi2A polypeptide equivalent; and
(b) an antigen, a nucleic acid encoding an antigen, or a cell expressing or presenting an antigen;
wherein the composition induces a humoral or cell-mediated immune response when administered to a subject.
242. The pharmaceutical composition of claim 241, wherein the antigen is comprised in an antigen-presenting cell.
243. The pharmaceutical composition of claim 241, further comprising an adjuvant.
244. The pharmaceutical composition of claim 241, wherein the humoral or cell-mediated immune response is against a tumor in a subject.
245. The pharmaceutical composition of claim 244, wherein the tumor is further defined as a breast cancer, lung cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, lymphoma, or leukemia.
246. The pharmaceutical composition of claim 241, wherein the humoral or cell-medicated immune response is against a virus in the subject.
247. The pharmaceutical composition of claim 246, wherein the virus is HIV, HSV, or ADV.